https://charts.traderzeitung.de/phases/US37611X2099 string(1495) "{"isin":"US37611X2099","name":"Ginkgo Bioworks Holdings Inc","stock_id_xnas":null,"stock_id_xnys":65845441,"generated_at":"2026-09-24 01:34:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":8.13,"close_at":"2026-09-21 15:22:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.98,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":-1.845},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":8,"close_at":"2026-09-21 22:59:00","complete":true,"perf_pct":0.2506}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":9.36,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":17},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":9.34,"close_at":"2026-09-23 01:17:00","complete":true,"perf_pct":-0.2137}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":9.05,"close_at":"2026-09-23 15:22:00","complete":true,"perf_pct":-3.1049},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":8.575,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-5.2486},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":8.65,"close_at":"2026-09-23 22:05:00","complete":false,"perf_pct":0.8746}]}]}"

Ginkgo Bioworks Holdings Aktie News & Nachrichten

[WKN: A40KL9 | Symbol: DNA]

Realtimekurs

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Ginkgo Bioworks Holdings gefunden werden.

Ginkgo Bioworks Holdings Nachrichtenticker öffnen

MT Newswires 16.09.2026 16:36 Uhr

Ginkgo Bioworks Holdings Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Ginkgo Datapoints liefert Entdeckungsdaten für Eli Lillys TuneLab-Netzwerk

Gingko Bioworks erhält ARPA-H-Unterauftrag im Wert von bis zu 17,5 Millionen US-Dollar für die RNA-Produktion

TD Cowen stuft Ginkgo Bioworks von Buy auf Hold herab und passt das Kursziel von $12 auf $9 an